The interaction of drugs to treat cardiovascular diseases and testosterone therapy, their effects and characteristics

Testosterone is used in the treatment of primary or acquired hypogonadism, constitutional growth retardation, and delayed puberty in male patients. Today, there is a fact that cardiovascular diseases present a high frequency in males with a marked tendency to increase soon. Therefore, the number of men using drugs to treat cardiovascular diseases is increasing rapidly. Cardiovascular drugs, which are frequently used and/or recently introduced, may cause undesirable effects under the heading of drug-drug interaction with testosterone therapy. The number of male patients exposed to these agents may increase rapidly quite soon. In this paper, we reviewed the potential drug-drug interactions between drugs to treat cardiovascular diseases and testosterone treatment considering the pharmacokinetic parameters and experimental animal studies in the literature.

Testosterone; Drug interactions; Drug-induced; Cardiovascular drugs

[1] Yeap BB, Wu FCW. Clinical practice update on testosterone therapy for male hypogonadism: Contrasting perspectives to optimize care. Clinical Endocrinology. 2019; 90: 56-65.

[2] Yeap BB, Alfonso H, Chubb SA, Handelsman DJ, Hankey GJ, Almeida OP, et al. In older men, higher plasma testosterone or dihydrotestosterone are independent predictors for reduced incidence of stroke but not myocardial infarction. The Journal of Clinical Endocrinology & Metabolism. 2014; 99: 4565-4573.

[3] Yeap BB, Alfonso H, Chubb SA, Handelsman DJ, Hankey GJ, Almeida OP, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. The Journal of Clinical Endocrinology & Metabolism. 2014; 99: E9-18.

[4] Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. the New England Journal of Medicine. 2010; 363: 109-122.

[5] Ambrisentan-drug information. Available at: https://www. uptodate.com/contents/ambrisentan-druginformation (Accessed: 1 October 2020).

[6] Hansten PD, Horn JR. Cytochrome P450 enzymes and drug interac-tions, table of cytochrome P450 substrates, inhibitors, inducers and p-glycoprotein, with footnotes. In: the top 100 drug interactions-a guide to patient management. Freeland, WA: H&H Publications. 2008; 142-157.

[7] Review Editor B. Letairis (ambrisentan) PharmaDeals Review. 2007.

[8] AMBRİSENTAN. Available at: https://www. micromedexsolutions.com/reprotox (Accessed: 1 September 2020).

[9] Carvedilol-drug-information. Available at: https://www. uptodate.com/contents/carvedilol-drug-information (Accessed: 5 October 2020).

[10] Barnes KM, Dickstein B, Cutler GB Jr, Fojo T, Bates SE. Steroid treat-ment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry. 1996; 35: 4820-4827.

[11] Food and Drug Administration (FDA). Drug development and drug interactions. 2012. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInte (Accessed: 13 October 2020).

[12] Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Character-ization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundamental & Clinical Pharmacology. 2006; 20: 273-282.

[13] GlaxoSmithKline. Coreg product label. 2017. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo. cfm?setid=c57982f2-c7da-488a-7ea9-b9609439ac68(Accessed: 13 October 2020).

[14] Morsy M, Ramzy M, El-Sheikh AK, Kamel M, Abdelwahab S. Mechanism of testicular protection of carvedilol in streptozotocin-induced diabetic rats. Indian Journal of Pharmacology. 2014; 46: 161.

[15] Conivaptan-drug-information. Available at: https://www. uptodate.com/contents/conivaptan-drug-information (Accessed: 8 October 2020).

[16] Vaprisol (conivaptan hydrochloride injection) package insert. Deer-field, IL: Baxter Healthcare Corporation. 2016.

[17] Krauser JA, Guengerich FP. Cytochrome P450 3A4-catalyzed testos-terone 6beta-hydroxylation stereochemistry, kinetic deuterium iso-tope effects, and rate-limiting steps. Journal of Biological Chemistry. 2005; 280: 19496-19506.

[18] Drug Development and Drug Interactions. Table of Substrates, Inhibitors and Inducers. 2020. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm (Accessed: 8 October 2020).

[19] Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation. Alphen aan den Rijn, The Netherlands. 2017.

[20] Boehringer Ingelheim Pharmaceuticals. Product information: Pradaxa. Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals. 2018.

[21] Dabigatran-drug-information. Available at: https://www. uptodate.com/contents/dabigatran-drug-information (Accessed: 7 September 2020).

[22] Pradaxa (dabigatran) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 2020.

[23] Dronedarone-drug-information. Available at: https://www. uptodate.com/contents/dronedarone-drug-information (Accessed: 7 September 2020).

[24] Multaq (dronedarone) package insert. Bridgewater, NJ: Sanofi-aventis. 2014.

[25] Daiichi Sankyo. Product information: Savaysa. Tokyo, Japan, Daiichi Sankyo. 2015.

[26] Edoxaban-drug-information. Available at: https://www. uptodate.com/contents/edoxaban-drug-information (Accessed: 6 October 2020).

[27] Savaysa (edoxaban) package insert. Basking Ridge, NJ: Daiichi Sankyo, Inc. 2020.

[28] Edoxaban. Available at: https://www.micromedexsolutions. com/reprotox (Accessed: 1 October 2020).

[29] Propranolol-drug-information. Available at: https://www. uptodate.com/contents/propranolol-drug-information (Accessed: 1 October 2020).

[30] Androgel 1% (testosterone gel) package insert. North Chicago, IL: Abbott Laboratories. 2019.

[31] Ranolazine-drug-information. Available at: https://www.uptodate.com/contents/ranolazine-drug-information (Accessed: 20 September 2020).

[32] Ranexa (ranolazine extended-release tablets) package insert. Foster City, CA: Gilead Sciences, Inc. 2019.

[33] Janssen Pharmaceuticals Product information: Xarelto. Janssen Phar-maceuticals. 2011.

[34] Rivaroxaban-drug-information. Available at: https://www. uptodate.com/contents/rivaroxaban-drug-information (Accessed: 13 September 2020).

[35] Xarelto (rivaroxaban) package insert. Janssen Pharmaceuticals. 2020.

[36] Astra Zeneca. Product information: Brilinta. Cambridge, UK, As-traZeneca. 2011.

[37] Ticagrelor-drug-information. Available at: https://www. uptodate.com/contents/ticagrelor-drug-information (Accessed: 13 September 2020).

[38] Barnes KM, Dickstein B, Cutler, GB, Fojo T, Bates SE. Steroid trans-port, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry. 1996; 35: 4820-4827.

[39] Brilinta (ticagrelor) package insert. Wilmington, DE: AstraZeneca LP. 2020.

[40] Tolvaptan-drug-information. Available at: https://www. uptodate.com/contents/tolvaptan-drug-information (Accessed: 13 September 2020).

[41] Samsca (tolvaptan) package insert. Tokyo, Japan: Otsuka Pharmaceu-ticals Co., Ltd. 2017.

[42] Warfarin-drug-information. Available at: https://www. uptodate.com/contents/warfarin-drug-information (Accessed: 2 September 2020).

[43] Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Annals of Internal Medicine. 1994; 121: 676-683.

[44] Androderm (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc. 2020.

[45] Dapagliflozin-drug-information. Available at: https: //www.uptodate.com/contents/dapagliflozin-drug-information (Accessed: 29 September 2020).

[46] Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity, and partial androgen deficiency. Aging Male. 2003; 6: 1-7.

[47] Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replace-ment therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology. 2006; 154: 899-906.

[48] Hobbs CJ. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. Journal of Clinical Endocrinology & Metabolism. 1996; 81: 1582-1585.

[49] Corrales JJ, Burgo RM, Garcı́a-Berrocal B, Almeida M, Alberca I, González-Buitrago JM, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism. 2004; 53: 666-672.

[50] Lee C, Kuo S, Hung Y, Hsieh C, He C, Yang T, et al. The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocrine Research. 2005; 31: 139-148.

[51] Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. The Journal of Clinical Endocrinology & Metabolism. 1987; 64: 960-963.

[52] Astra Zeneca Pharmaceuticals LP. Farxiga product labeling. 2019. Availabie at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69 (Accessed: 29 September 2020).

[53] FDA Pharmacology Review. 2014. Available at: https: //www.accessdata.fda.gov/drugsatfda_docs/nda/2014/ 202293Orig1s000TOC.cfm (Accessed: 30 September 2020).

[54] Empagliflozin-drug-information. Available at: https: //www.uptodate.com/contents/empagliflozin-drug-information (Accessed: 30 September 2020).

[55] Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance labeling. 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&type=display (Accessed: 30 September 2020).

[56] Jardiance pharmacology review. 2011. Available at: http: //www.accessdata.fda.gov/drugsatfda_docs/nda/2011/ 201280Orig1s000PharmR.pdf (Accessed: 30 September 2020).

[57] Ertugliflozin-drug-information. Available at: https: //www.uptodate.com/contents/ertugliflozin-drug-information (Accessed: 30 September 2020).